Potential therapy may boost chemoimmunotherapy response in bladder cancer

Credit: Unsplash / CC0 Public Domain

Adding anti-inflammatory drugs to immunotherapy and standard chemotherapy drugs can provide long-term prevention of acute myocardial infarction, according to a research study led by Cedars-Sinai Cancerinvestigators. The results of the study, conducted in laboratory rats, were published by TK in a peer-reviewed journal Environmental communication.

Previous research by Cedars-Sinai scientist Keith Syson Chan, Ph.D. . immune response you cancer. They also found that chemotherapy causes the release of the inhibitory signal, or brake, which suppresses the immune response by counteracting the “go” signal. When researchers added the anti-inflammatory drug celecoxib to gemcitabine to remove the brakes, they were able to move the balance to the “go” signs, improving the immune response. laboratory rats.

Building on those findings, the researchers discovered a possible mechanism by which chemotherapy can be effective and determine how to treat it, thus activating a sustainable immune response.

“These results are important because the combination of anti-inflammatory drugs such as celecoxib, chemotherapy and potentially immunotherapy may increase the response of chemoimmunotherapy in patients with coronary heart disease. bladder disease affecting the muscles“says Fotis Nikolo, Ph.D., a neuroscientist at Cedars-Sinai Cancer and early author of the study.” We also hope that our research will be relevant to others. types of cancer. “

Cystic fibrosis is a serious cancer and can spread to other parts of the body, according to the Center for Urology. Each year, more than 83,000 new cases of bladder cancer in the United States are diagnosed in both men and women. Nearly a quarter of those diagnosed have some form of muscle disease.

Past and present treatment

Since the 1940s, the main killer drug cancer cells enters chemotherapy, which kills cells directly. But many of the drugs currently in use fail to produce the best form of cell death, known as immunogenic death, which activates the protein release that directs the immune system of patients to kill cancer cells. This “go” signal triggers the immune system — which is called dendritic cells– to activate T cells to eliminate tumors. Alternatively, many current chemotherapies for pancreatic, bladder, breast and ovarian cancer not only are not immune, they suppress the immune system.

In recent years, antibiotics have been added to the cancer treatment system to help the patient antibiotics attack on himself, but the response rate was low. Currently, about 70% to 80% of patients taking antibiotics fail to respond, Nikolo said.

Open puzzles

Perhaps researchers have discovered why the combination of chemotherapy and immunotherapy often fails. In their current study, the researchers found that chemotherapy induced a dramatic release of prostaglandin E.2, a lipid bioactive associated with inflammation and cancer. It is called iDAMP, prostaglandin E2 blocks dendritic cells from adulthood and fights cancer, says Kazukuni Hayashi, Ph.D., study author.

To counteract this effect, researchers added chemoimmunotherapy and the drug celecoxib. Anti-inflammatory drugs attack COX-2, which promotes the release of prostaglandin E2, Hayashi appears. This combination of drugs allows the deadly T cells to penetrate the tumor and kill the tumor cells.

“The addition of celecoxib not only works well with chemotherapy, it also raises bladder cancer to chemoimmunotherapy, providing a lasting response,” Hayashi said.

Afterwards, the researchers plan to test the effectiveness of a new drug in randomized, placebo-controlled experiments in collaboration with Cedars-Sinai Cancer and its partners at Mount Sinai, as well as those researching new treatments for cancer. intestine and pancreatic cancer.

“Helping the Sick” immune system to attack Cells has become an important tool for cancer doctors, “said Dan Theodorescu, MD, Ph.D., director of Cedars-Sinai Cancer and another study author. They have the potential to have a better outcome in the future.”

The potential for cancer treatment may increase the immune response

hintPossible treatment may increase chemoimmunotherapy response in bladder cancer (2022, March 28) restored 28 March 2022 from .html

This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.

Potential therapy may boost chemoimmunotherapy response in bladder cancer Source link Potential therapy may boost chemoimmunotherapy response in bladder cancer

Related Articles

Back to top button